{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:31:48Z","timestamp":1725409908097},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"DOI":"10.7759\/cureus.68563","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:55:04Z","timestamp":1725396904000},"source":"Crossref","is-referenced-by-count":0,"title":["Aggressive Course of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): An Illustration of Two Cases and Review of Literature"],"prefix":"10.7759","author":[{"given":"Heitor C","family":"Frade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awab","family":"Elnaeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankhuri","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tripti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Dabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol CL","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, et al.. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020, 26:806-14. 10.1177\/1352458519845112","journal-title":"Mult Scler"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell K","year":"2020","unstructured":"O'Connell K, Hamilton-Shield A, Woodhall M, et al.. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020, 91:1126-8. 10.1136\/jnnp-2020-323158","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103884","article-title":"Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy","volume":"63","author":"Orlandi R","year":"2022","unstructured":"Orlandi R, Mariotto S, Gajofatto A. Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. Mult Scler Relat Disord. 2022, 63:10.1016\/j.msard.2022.103884","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","article-title":"Studies on autoimmune encephalomyelitis in the Guineapig: ii. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor","volume":"116","author":"Lebar R","year":"1976","unstructured":"Lebar R, Boutry JM, Vincent C, et al.. Studies on autoimmune encephalomyelitis in the Guineapig: ii. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor. J Immunol. 1976, 116:1439-46.","journal-title":"J Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(84)90064-x","article-title":"A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody","volume":"6","author":"Linnington C","year":"1984","unstructured":"Linnington C, Webb M, Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol. 1984, 6:387-96. 10.1016\/0165-5728(84)90064-x","journal-title":"J Neuroimmunol"},{"key":"ref6","article-title":"The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane","volume":"66","author":"Lebar R","year":"1986","unstructured":"Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry JM. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol. 1986, 66:423-34.","journal-title":"Clin Exp Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(87)90031-2","article-title":"Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin\/oligodendrocyte glycoprotein (MOG)","volume":"17","author":"Linington C","year":"1987","unstructured":"Linington C, Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin\/oligodendrocyte glycoprotein (MOG). J Neuroimmunol. 1987, 17:61-9. 10.1016\/0165-5728(87)90031-2","journal-title":"J Neuroimmunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2006.04.006","article-title":"Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis","volume":"109","author":"Zadro I","year":"2007","unstructured":"Zadro I, Brinar V, Horvat G, Brinar M. Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis. Clin Neurol Neurosurg. 2007, 109:23-6. 10.1016\/j.clineuro.2006.04.006","journal-title":"Clin Neurol Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(91)90014-x","article-title":"Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosisand controls","volume":"31","author":"Xiao BG","year":"1991","unstructured":"Xiao BG, Linington C, Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosisand controls. J Neuroimmunol. 1991, 31:91-6. 10.1016\/0165-5728(91)90014-x","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-3940(01)01949-8","article-title":"Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100b and myelin basic protein in patients with Devic\u2019s neuromyelitis optica","volume":"307","author":"Haase CG","year":"2001","unstructured":"Haase CG, Schmidt S. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100b and myelin basic protein in patients with Devic\u2019s neuromyelitis optica. Neurosci Lett. 2001, 307:131-3. 10.1016\/s0304-3940(01)01949-8","journal-title":"Neurosci Lett"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger R","year":"2015","unstructured":"H\u00f6ftberger R, Sepulveda M, Armangue T, et al.. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015, 21:866-74. 10.1177\/1352458514555785","journal-title":"Mult Scler"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters P","year":"2015","unstructured":"Waters P, Woodhall M, O'Connor KC, et al.. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015, 2:10.1212\/NXI.0000000000000089","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo A","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, et al.. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018, 90:e1858-69. 10.1212\/WNL.0000000000005560","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen Y","year":"2018","unstructured":"Hacohen Y, Palace J. Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology. 2018, 90:947-8. 10.1212\/WNL.0000000000005619","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl M","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019, 15:89-102. 10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4015075","article-title":"Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China","volume":"2019","author":"Song H","year":"2019","unstructured":"Song H, Zhou H, Yang M, et al.. Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol. 2019, 2019:10.1155\/2019\/4015075","journal-title":"J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk M","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al.. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017, 140:3128-38. 10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10914-x","article-title":"Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"269","author":"Akaishi T","year":"2022","unstructured":"Akaishi T, Misu T, Fujihara K, et al.. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. J Neurol. 2022, 269:3136-46. 10.1007\/s00415-021-10914-x","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105130","article-title":"Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"81","author":"Martin K","year":"2024","unstructured":"Martin K, Srikanth P, Kanwar A, Falardeau J, Pettersson D, Yadav V. Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord. 2024, 81:10.1016\/j.msard.2023.105130","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211776","article-title":"Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands","volume":"14","author":"Tomizawa Y","year":"2023","unstructured":"Tomizawa Y, Hoshino Y, Kamo R, Cossu D, Yokoyama K, Hattori N. Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands. Front Immunol. 2023, 14:10.3389\/fimmu.2023.1211776","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker BG","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, et al..  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999, 46:878-86. 10.1002\/1531-8249(199912)46:6&lt;878::aid-ana10&gt;3.0.co;2-q","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10236-4","article-title":"Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis","volume":"268","author":"Lu Q","year":"2021","unstructured":"Lu Q, Luo J, Hao H, Liu R, Jin H, Jin Y, Gao F. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol. 2021, 268:4537-48. 10.1007\/s00415-020-10236-4","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam DH","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al.. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020, 44:10.1016\/j.msard.2020.102251","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000625","article-title":"Identification of circulating MOG-specific B cells in patients with MOG antibodies","volume":"6","author":"Winklmeier S","year":"2019","unstructured":"Winklmeier S, Schl\u00fcter M, Spadaro M, et al.. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019, 6:10.1212\/NXI.0000000000000625","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen JJ","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, et al.. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020, 95:e111-20. 10.1212\/WNL.0000000000009758","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease","volume":"10","author":"McLendon LA","year":"2023","unstructured":"McLendon LA, Gambrah-Lyles C, Viaene A, et al.. Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease. Neurol Neuroimmunol Neuroinflamm. 2023, 10:10.1212\/NXI.0000000000200150","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07189-7","article-title":"Tocilizumab treatment in MOGAD: a case report and literature review","volume":"45","author":"Schir\u00f2 G","year":"2024","unstructured":"Schir\u00f2 G, Iacono S, Andolina M, Bianchi A, Ragonese P, Salemi G. Tocilizumab treatment in MOGAD: a case report and literature review. Neurol Sci. 2024, 45:1429-36. 10.1007\/s10072-023-07189-7","journal-title":"Neurol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/274219-aggressive-course-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-an-illustration-of-two-cases-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:55:08Z","timestamp":1725396908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/274219-aggressive-course-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-an-illustration-of-two-cases-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.68563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}